CellKey
CellKey AI is a South Korean biotech that builds an AI-powered multiomics and glycoproteomics analysis platform (SpAC9 Data Foundry, BioEOS) serving pharmaceutical, biotech, hospital, and academic customers for drug development, biomarker discovery, and early cancer diagnostics, with global expansion into the US, Japan, and the Middle East.
- Company typePrivate
- Founded2019
- HeadquartersCheongju, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What CellKey does
CellKey AI Inc. (주식회사 셀키에이아이) is a South Korea-based biotech company founded in May 2019 and headquartered in the Osong Bio Cluster in Cheongju, with additional offices in Seoul and Torrance, California. The company builds an AI-driven multiomics analysis platform — anchored by the SpAC9 Data Foundry (a cloud-based SaaS platform for proteomics, glycoproteomics, and metabolomics data) and the proprietary One-Stop glycopeptide analysis technology, which processes glycoproteins as a unified entity and is claimed to deliver up to 100x faster analysis and 50% lower cost versus conventional methods. Its product portfolio also includes the SpAC9 AI Platform for DDA/DIA data analysis, BioEOS (a bio-vertical AI agent for R&D workflow automation), an LLM-based Multiomics AI Agent in co-development, and an AI-nanoplasmonic early liver cancer diagnostic device under joint development with Harvard MGH. The company achieved 99% accuracy at the 2019 HGI Glycopeptide Analysis Competition and holds GMP certification for its liver cancer early diagnostic product.
CellKey monetizes through a hybrid model combining professional services (multiomics analysis, biomarker co-development, companion diagnostics R&D for pharmaceutical, biotech, and academic customers) with a recurring SaaS revenue stream via the SpAC9 Data Foundry, which launched a freemium trial campaign in mid-2025. Enterprise customers include major Korean pharmaceutical and biotech companies, Korean university hospitals, and international collaborators including Harvard MGH, University College London, and Weill Cornell Medicine-Qatar Center. Go-to-market is sales-led enterprise field sales supplemented by partnership-driven co-development (D&T&C&R&O, MegazoneCloud, Charparral Labs, Protium Science, Molecular Design Research Center) and government-recognized designations (Innovative Product, Excellent Corporate Research Lab) that support public procurement and regulatory progression.
The company is led by founder-CEO Lee Nam-yong (formerly a software engineer at Samsung Electronics, Korea AWS, and Microsoft), supported by COO Lee Sang-yong and Bioinformatics Research Institute Director Park Geon-wook. CellKey has raised a Series A from D&T&C&R&O (March 2024) alongside earlier rounds from D3 Jubilee, Riga Investment, and ETRI Holdings, and was selected for Korea's Super Gap Startup 1000+ program in 2025. The firm is positioned as the only glycoproteomics-specialized company in Korea and one of only two globally, with active global expansion into the US, Japan, the Middle East, and Europe.
CellKey firmographics
Firmographics- Name
- CellKey
- Legal name
- (주)셀키에이아이
- Website
- https://cellkey.co.kr
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CellKey AI is a South Korean biotech that builds an AI-powered multiomics and glycoproteomics analysis platform (SpAC9 Data Foundry, BioEOS) serving pharmaceutical, biotech, hospital, and academic customers for drug development, biomarker discovery, and early cancer diagnostics, with global expansion into the US, Japan, and the Middle East.
- Ownership category
- akta.pro rank
CellKey industry classification
Industry- Product category
- Bioinformatics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151), Computer Systems Design and Related Services (54151)
- SIC
- Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
Keywords
Where CellKey is headquartered
LocationHeadquarters
- HQ city
- Cheongju
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
CellKey business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Multiomics Analysis Services: Provides high-resolution mass spectrometry-based proteomics, glycoproteomics, and metabolomics analysis services to pharmaceutical companies, biotech firms, research institutes, and hospitals. Services include antibody-drug and ADC analysis for new drug development, as well as food and environmental sample analysis.
- SpAC9 Data Foundry SaaS Platform: Cloud-based SaaS platform subscription for multiomics data analysis with 100 credits (33GB) free trial for 30 days. Platform provides DDA/DIA search, re-search, re-analysis, and DEP reselection capabilities without batch effects.
- Biomarker Development Services: Collaborative research services with hospitals and pharmaceutical companies for clinical sample-based multiomics data analysis to develop early disease diagnosis and drug response prediction biomarkers.
- Companion Diagnostics R&D: R&D services for drug development companies focused on companion diagnostics development based on multiomics analysis.
- Global Glycoprotein Analysis Services: International expansion of glycoprotein analysis services to US, Middle East, Europe, and Japan markets. Services include liver cancer early diagnosis product (GMP certified) and lung cancer early diagnosis products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Free Trial - 100 credits (33GB) |
| Subscription | Annual | Enterprise/Custom Pricing |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
CellKey product offering
Product offeringCore offering
CellKey provides an AI-driven multiomics analysis platform (SpAC9 Data Foundry) and bio-vertical AI agent (BioEOS) that deliver glycoprotein, proteomics, and metabolomics analysis for pharmaceutical, biotech, hospital, and research institution customers. The company also offers professional multiomics analysis services, biomarker discovery for early disease diagnosis (liver cancer, lung cancer), and companion diagnostics R&D support. Its proprietary One-Stop glycoprotein analysis technology enables unified analysis of glycoproteins, achieving up to 100x faster processing and over 50% cost reduction versus traditional methods.
Product overview
CellKey offers a unified platform-plus-services portfolio anchored by the SpAC9 Data Foundry, a cloud-based SaaS multiomics analysis platform, complemented by the BioEOS bio-vertical AI agent and an LLM-based Multiomics AI Agent. These core AI-driven platforms are delivered alongside two service lines: Multiomics Services (high-resolution mass spectrometry-based proteomics, glycoproteomics, and metabolomics analysis) and Biomarker Services (clinical sample-based AI-powered biomarker discovery for early disease diagnosis). The company also develops a CDMO AI optimization solution for biopharmaceutical manufacturing and an AI-nanoplasmonic early liver cancer diagnostic device in partnership with Harvard MGH.
Differentiator
Problem solved
Functional benefit
Brands
- SpAC9 Data Foundry: AI-powered cloud-based SaaS platform for multiomics data analysis without batch effect, processing LC-MS/MS and multiomics data
- BioEOS
- SpAC9 AI Platform
Products and services
- SpAC9 Data Foundry (스팩9 데이터 파운드리) Cloud-based SaaS multiomics analysis platform that processes LC-MS/MS and multiomics data (proteomics, glycoproteomics, metabolomics) with batch-effect-free standardization across hundreds to thousands of samples. Offers DDA/DIA Search, Re-Search, Re-Analysis, and DEP Reselection capabilities at up to 100x faster analysis speed than CPU-based solutions, with biological functional analysis integration to GO, KEGG, Pfam, Reactome, InterPro, Phosida, and STRING databases.
- BioEOS (바이오이오스) Bio-vertical AI agent that precisely analyzes and automates bio data and workflows using AI, providing biological insights to support R&D decision-making for pharmaceutical and biotech companies. Analyzes multimodal data including omics, EMR (electronic medical records), and pathology images, and integrates AI agents for scientific evidence search and research report automation.
- Multiomics Analysis Services
Quantifiable outcome
- Up to 100x faster analysis speed with SpAC9 Data Foundry compared to CPU-based solutions
- +3 more outcomes
Companies that use CellKey
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
CellKey technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration7 records
AI capability7 records
Feature7 records
CellKey partnerships and signals
Strategic signalScale indicators8 records
Recent moves6 records
Expansion highlights7 records
CellKey competitors and assessment
Company assessmentDirect peers
- Seer: US proteomics platform company combining proprietary sample preparation with AI-driven analysis of large-scale proteomic datasets for biomarker discovery. Closely comparable to CellKey in offering an integrated platform-and-services proteomics offering to pharma/biotech.
- Nautilus Biotechnology:
- Interven Biosciences: US-based glycoproteomics company explicitly cited in CellKey's own materials as one of only two companies globally (alongside CellKey) utilizing glycoprotein technology for diagnostics. Most directly comparable peer in glycoproteomics-based diagnostic applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CellKey social profiles
Digital presenceCellKey compliance and trust
Trust signalCompliance3 records
CellKey financial estimates
Financial estimateRevenue estimate
Valuation estimate
CellKey leadership team
Management profileNumber of profiles
Profiles3 records
CellKey funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CellKey M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CellKey
What does CellKey do?
CellKey provides an AI-driven multiomics analysis platform (SpAC9 Data Foundry) and bio-vertical AI agent (BioEOS) that deliver glycoprotein, proteomics, and metabolomics analysis for pharmaceutical, biotech, hospital, and research institution customers. The company also offers professional multiomics analysis services, biomarker discovery for early disease diagnosis (liver cancer, lung cancer), and companion diagnostics R&D support. Its proprietary One-Stop glycoprotein analysis technology enables unified analysis of glycoproteins, achieving up to 100x faster processing and over 50% cost reduction versus traditional methods.
Is CellKey a public or private company?
CellKey is a private company. It is classified as venture growth investor backed and is currently operating.
When was CellKey founded?
CellKey was founded in 2019. It employs 11 to 50 people.
Where is CellKey based?
CellKey is headquartered in Cheongju, South Korea, in the Asia region.
How does CellKey make money?
Five revenue lines are on record. Multiomics Analysis Services are the primary driver. The others are spAC9 Data Foundry SaaS Platform, biomarker Development Services, companion Diagnostics R&D and global Glycoprotein Analysis Services.
Who are CellKey's main competitors?
Direct peers on record are Seer, Nautilus Biotechnology and Interven Biosciences.
Does CellKey have an API?
No public API is recorded for CellKey.
What industry is CellKey in?
CellKey's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.